Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1544)	3/14/2000 9:52:00 AM
From: scaram(o)uche	Respond to of 4974

Dain Rauscher is prominent on this one. We noted the increase in activity for Pacific Growth recently....... Tuesday March 14, 8:27 am Eastern Time Company Press Release LJL BioSystems Files Registration Statement for Common Stock Offering of 2.5 Million Shares SUNNYVALE, Calif.--(BUSINESS WIRE)--March 14, 2000--LJL BioSystems, Inc. (Nasdaq:LJLB - news) today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed offering of up to 2.5 million shares of its Common Stock, excluding 375,000 shares issuable upon exercise of the underwriters' overallotment option. All of the shares offered will be sold by the Company. FleetBoston Robertson Stephens and Chase H&Q, a division of Chase Securities Inc., will act as co-lead underwriters of the offering with Dain Rauscher Wessels acting as co-manager. (snip) Adams, Harkness & Hill.......... Tuesday March 14, 8:19 am Eastern Time Company Press Release SOURCE: Emisphere Technologies, Inc. Emisphere Technologies, Inc. Completes Offering of 2,750,000 Shares of Common Stock TARRYTOWN, N.Y., March 14 /PRNewswire/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS - news) today announced the completion of an offering of 2,750,000 shares of common stock at a price of $72.75 per share. Chase H&Q, Deutsche Banc Alex. Brown, Warburg Dillon Read LLC, and Adams, Harkness & Hill, Inc. served as underwriters for the offering. Emisphere received approximately $188 million after expenses. Proceeds from the offering will be used to fund development of preclinical stage programs, to fund the Phase III clinical program for oral heparin, and for general corporate purposes. After the offering, Emisphere has approximately 17.3 million shares outstanding. (snip) $190 million. The world has changed. The companies that have filled in behind the valuations will sit at the bargaining table with new found strength. They'll need the big-science companies that have not "filled" as partners going forward. A new plateau for the sector. Congrats, all!

To: nigel bates who wrote (1544)	3/14/2000 10:24:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

$30 million, round B.... how times have changed. Cash, hot cash, continues to roll into the sector...... Tuesday March 14, 10:00 am Eastern Time Company Press Release SOURCE: Seattle Genetics, Inc. Seattle Genetics, Inc. Completes $30 Million Financing to Expand Monoclonal Antibody-Based Therapy Programs BOTHELL, Wash., March 14 /PRNewswire/ -- Seattle Genetics, Inc., has raised $30 million in private financing to fight cancer. The Series B financing was led by Bank of America Ventures. Additional investors include Cascade Investment, Vulcan Ventures, Olympic Venture Partners, Sofinnova Ventures, and Indosuez Ventures. ``We're very pleased to have such a strong group of investors on board as we expand all aspects of operations within the company,' stated President and C.E.O. Perry Fell. According to Executive Vice President and Chief Scientific Officer Clay Siegall, ``Seattle Genetics plans to significantly increase the number of studies for its lead monoclonal antibody agents currently in clinical trials, and to bring forward several new candidates for development.' This financing will also help Seattle Genetics continue to expand its strategic alliances. Currently, the company has a license agreement with Genentech, Inc. to develop certain anti-cancer agents. Seattle Genetics also has in-license agreements with Bristol-Myers Squibb, Mabtech AB (Sweden), Arizona State University, and the University of Miami (Fla.) that have added key technologies related to monoclonal antibody targeted therapy. Seattle Genetics presently has two monoclonal antibody-based drugs in clinical trials, SGN-15 and SGN-10; both drugs target a variety of carcinomas including breast, lung, colon, and prostate. ``We are very excited to be evaluating two agents in clinical trials that deliver cytotoxic moieties to cancer cells via monoclonal antibody targeting,' said Medical Director, Dr. Amy Sing. SGN-15 is a chimeric monoclonal antibody that is conjugated to the cytotoxic drug doxorubicin. As part of a recently initiated phase I/II clinical program in breast and colon carcinoma, SGN-15 has been safely given to multiple cohorts of patients as part of a combination regimen with chemotherapy. Clinical studies are also planned with SGN-15 in prostate and lung carcinomas. SGN-10 is a genetically engineered immunotoxin fusion protein that has been safely administered to over 40 cancer patients as part of a single-agent phase I program. In addition, the company recently filed an Investigational New Drug (IND) application to initiate clinical trials of SGN-10 in combination with chemotherapy. Preclinical studies have shown that the combination of SGN-10 and taxanes results in synergistic antitumor activity in models of colon, breast, lung, and prostate carcinomas. Seattle Genetics has exciting research and development programs that utilize four technology platforms: 1. engineered monoclonal antibodies; 2. antibody-drug conjugates; 3. single-chain immunotoxins; and 4. antibody-directed enzyme/prodrug therapy (ADEPT). Using these platforms, the company can develop antitumor agents with any monoclonal antibody that has appropriate tumor specificity whether the antibody signals directly, internalizes, or remains on the cell surface. The company is currently developing several novel agents including SGN-14 and SGN-30 for hematologic malignancies and SGN-17/19 for metastatic melanoma. The Small Business Innovation Research Program at the National Cancer Institute recently awarded a grant to Seattle Genetics for work to be done using the ADEPT platform. Seattle Genetics is a privately held biotechnology company developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and immunologic disease. For more information about Seattle Genetics, Inc., contact the website at www.seattlegenetics.com or call Larry Benedict at 425-489-4999. Seattle Genetics, Inc., Bothell, WA Contact: Larry Benedict 425-489-4999 SOURCE: Seattle Genetics, Inc.